iwNHL 2015 roundtable: Day 2 highlights – PI3K inhibitors

John Gribben, MD, DSc, FRCPath, FRCP FMedSci, of Barts and The London School of Medicine and Dentistry, London, UK, chairs a discussion with Wyndham Wilson, MD, PhD, on the highlights from the second day of the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting. They review the clinical development of inhibitors targeting the phosphoinositide 3-kinase (PI3K) pathway, as single agents and in combination with other therapies, for the treatment of patients with non-Hodgkin lymphoma.

Share this video  
3rd October 2015